CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria HONG KONG, China and WILMINGTON, Del. –1 April, 2024 –China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”)…